Considerations in the design of clinical trials of neuroprotective therapy in acute stroke

Stroke

Volumn 27, Issue 9, 1996, Pages 1507-1515

  Dorman, Paul J ^a   Sandercock, Peter A G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 PHOSPHONOMETHYLPIPECOLIC ACID; APTIGANEL; CLOMETHIAZOLE; DEXTROMETHORPHAN; DEXTRORPHAN; ELIPRODIL; MAGNESIUM; MONOSIALOGANGLIOSIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PROPENTOFYLLINE;

ARTICLE; CLINICAL TRIAL; DRUG RESEARCH; DRUG SAFETY; HUMAN; NEUROPROTECTION; PATIENT SELECTION; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

EID: 0029815102     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.9.1507     Document Type: Article

References (85)

1. Sandercock PAG, Celani MG, Ricci S. The likely public health impact in Europe of simple treatments for acute ischaemic stroke. Cerebrovasc Dis. 1992;2:236. Abstract.
2. Sandercock PAG, Willems H. Medical treatment of acute ischaemic stroke. Lancet. 1992;339:537-539.
3. Heiss W-D, Graf R. The ischaemic penumbra. Curr Opin Neural. 1994;7:11-19.
4. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
5. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol. 1992;34:106-114.
6. Counsell C, Sandercock PAG. The management of patients with acute ischaemic stroke. Curr Med Lit Ger. 1995;7:99-110.
7. Dorman PJ, Counsell C, Sandercock PAG. Recently developed neuroprotective therapies for acute stroke: a qualitative systematic review of clinical trials. CNS Drugs. 1996;5:457-474.
8. Davis SM, Donnan A. Patients, centres, admission procedures and non-randomized treatments around the world. Cerebrovasc Dis. 1995;5(suppl 1):16-21.
9. Bogousslavsky J. Acute stroke trials: from morass to nirvana? Cerebrovasc Dis. 1995;5:3-6.
10. van Gijn J. Extrapolation of trials data into practice: where is the limit? Cerebrovasc Dis. 1995;5:159-162.
11. Sandercock P. Major ongoing stroke trials: the International Stroke Trial-Main. Stroke. 1995;26:1142. Abstract.
12. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349-360.
13. ISIS-3 Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
14. Adams RJ, Fisher M, Furlan AJ, del Zoppo G. Acute stroke treatment trials in the United States: rethinking strategies for success. Stroke. 1995;26:2216-2218.
15. Trust Study Group. Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet. 1990;336:1205-1209.
16. Rothwell PM, Warlow CP. The European Carotid Surgery Trial (ECST). In: Greenhalgh RM, Hollier LH, eds. Surgery for Stroke. London, UK: WB Saunders Co; 1993.
17. Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke. 1995;26:2219-2221.
18. Fisher M, Bogousslavsky J. Evolving toward effective therapy for acute ischemic stroke. JAMA. 1993;270:360-364.
19. Frey JL. The future of acute stroke treatment: lessons we have learned from laboratory and clinical research. Arch Intern Med, 1995; 155:1005.
20. Barsan WG, Brott TG, Broderick JP, Haley EC, Levy DE, Marier JR. Urgent therapy for acute stroke: effects of a stroke trial on untreated patients. Stroke. 1994;25:2132-2137.
21. Grotta J. The current status of neuronal protective therapy: why have all the neuronal protective drugs worked in animals but none so far in stroke patients? Cerebrovasc Dis. 1994;4:115-120.
22. Kay R, Wong K, Yu Y, Chan Y, Tsoi T, Ahuja A, Chan F, Fong K, Law C, Wong A, Woo J. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333:1588-1593.
23. Wise RJS, Bernardi S, Frackowiak RSJ, Legg NJ, Jones T. Serial observations on the pathophysiology of acute stroke: the transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain. 1983;106:197-222.
24. Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wienhard K. Progressive derangement of periinfarct viable tissue in ischemie stroke. J Cereb Blood Flow Metab. 1992;12:193-203.
25. Baron JC. Ischemic stroke studied by 150-labelled compounds: misery perfusion and luxury perfusion. In: Heiss WD, Pawlik G, Herholz K, Wienhard K, eds. Clinical Efficacy of Positron Emission Tomography. Boston, Mass/Dortrecht, Netherlands: Martinus Nijhoff Publishing; 1987:15-23.
26. Heiss WD, Fink GR, Huber M, Herholz K. Positron emission tomography imaging and the therapeutic window. Stroke. 1993;24 (suppl):I-50-I-53.
27. Warach S, Benfield A, Edelman RR. Prolonged evolution of lesion volume in human stroke determined by diffusion-weighted MRI. Neurology. 1995;45(suppl 4):287. Abstract.
28. Wiebers DO, Adams HP, Whisnant JP. Animal models of stroke: are they relevant to human disease? Stroke. 1990:21:1-3.
29. Mathur VS, Guinn GA, Burns WH. Maximal revascularization (reperfusion) in intacl conscious dogs after 2 to 5 hours of coronary occlusion. Am J Curdiol. 1975;36:252-261.
30. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death, I: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-792.
31. O'Brien CM, Carroll M, O'Rourke PT, Rhodes EL, Gago O, Kirsh MM, Morris JD, Sloan HE. The reversibility of acute ischemic injury to the myocardium by restoration of coronary flow. J Thorac Cardiovasc Surg. 1972;64:840-846.
32. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of plasminogen activator for mortality reduction in acute myocardial infarction: Anglo- Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530.
33. ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity and infarct size at 21 days. N Engl J Med. 1986;314:1465-1471.
34. Morris AD, Grosset DG, Squire IB, Lees KR, Bone I, Reid JL. The experiences of an acute stroke unit: implications for multicentre acute stroke trials. J Neurol Neurosurg Psychiatry. 1993;56:352-355.
35. LaRue LJ, Aler M, Traven ND, Sterman AB, Sobel E, Kleiner J. Acute stroke therapy trials: problems in patient accrual. Stroke. 1988;19:950-954.
36. Harper GD, Haigh RA, Potter JF, Castleden CM. Factors delaying hospital admission after stroke in Leicestershire. Stroke. 1992;23: 835-838.
37. Feldmann E, Gordon N, Brooks JM, Brass LM, Fayad PB, Sawaya KL, Nazareno F, Levine SR. Factors associated with early presentation of acute stroke. Stroke. 1993;24:1805-1810.
38. Alberts MJ, Bertels C, Dawson DV. An analysis of time of presentation after stroke. JAMA. 1990;263:65-68.
39. Alberts MJ, Perry A, Dawson DV, Bertels C. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke. 1992;23:352-356.
40. Wroe SJ, Sandercock P, Bamford J, Dennis M, Slattery J, Warlow C. Diurnal variation in incidence of stroke: Oxfordshire community stroke project. BMJ. 1992;304:155-157.
41. American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke. 1992;23:3-8.
42. Counsell CE, Clarke MJ, Slattery J. Sandercock PAG. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? BMJ. 1994;309:1677-1681.
43. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274:1017-1025.
44. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Star Med. 1987;6:245-250.
45. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
46. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-1986, II: incidence, case fatality and overall outcome at one year of cerebral infarction, primary intracerebral haemorrhage and subarachnoid haemorrhage. J Neural Neurosurg Psychiatry. 1990;53:16-22.
47. Tanaka H, Ueda Y, Date C, Baba T, Yamashita H, Hayashi M. Shoji H, Owada K, Baba K, Shibuya M, Kon T, Detels R. Incidence of stroke in Shibata, Japan: 1976-1978. Stroke. 1981;12:460-466.
48. Mendelow D. Spontaneous intracerebral haemorrhage. J Neural Neurosurg Psychiatry. 1991;54:193-195.
49. Nehls DG, Mendelow D, Graham DI, Sinar EJ, Teasdale GM. Experimental intracerebral hemorrhage: progression of hemodynamic changes after production of a spontaneous mass lesion. Neurosurgery. 1995;23:439-444.
50. Bullock R, McCulloch J, Graham DI, Lowe D, Chen MH, Teasdale GM. Focal ischemic damage is reduced by CPP-ene studies in two animal models. Stroke. 1990;21(suppl):III-32-III-36.
51. Choksey MS, Costa DC, Iannotti F, Ell PJ, Crockard HA. 99TCm-HMPAO SPECT studies in traumatic intracerebral haematoma. J Neural Neurosurg Psychiatry. 1991;54:6-11.
52. Dorman PJ, Sandercock PAG. Should patients with visible infarction on the admission CT scan be excluded from acute stroke trials? An analysis of data from 12,450 patients randomised in the IST. In: Program of the Meeting of the Association of British Neurologists; April 11-12, 1996; Norwich, UK. Abstract.
53. Saunders DE, Howe FA, van den Boogaart A, McClean MA, Griffiths JR, Brown MM. Continuing ischemic damage after acute middle cerebral artery infarction in humans demonstrated by short-echo proton spectroscopy. Stroke. 1995;26:1007-1013.
54. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phenylcyclidine and related drugs. Science. 1989;244:1360-1362.
55. Tatemichi TK, Desmond DW, Stern Y, Paik M, Sano M, Bagiella E. Cognitive impairment after stroke: frequency, patterns and relationship to functional abilities. J Neurol Neurosurg Psychiatry. 1994;57:202-207.
56. Anonymous. Clinical trials and clinical practice. Lancet. 1993;342: 877-878.
57. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet. 1993;342:891-894.
58. Freemantle N, Henry D, Maynard A, Torrance G. Promoting cost effective prescribing. BMJ. 1995;310:955-956.
59. van Gijn J, Warlow C. Down with stroke scales. Cerebrovasc Dis. 1992;2:244-246.
60. Peto R. Monitoring cancer patients in clinical trials need not be precise. In: Symington T, Williams AE, McVie JG, eds. Cancer: Assessment and Monitoring - Tenth Pfizer International Symposium. Edinburgh, Scotland: Churchill Livingstone Inc; 1980:377-381.
61. Lindley RI, Waddell F, Livingstone M, Warlow C, Dennis M, Sandercock PAG, Smith B. Can simple questions assess outcome after stroke? Cerebrovasc Dis. 1994;4:314-324.
62. The EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199-208.
63. Yatsu FM, Yeakley JW, Fenstermacher MJ. The role of neuro-imaging in acute ischaemic stroke therapy. In: Amery WK, Bousser M-G, Clifford Rose F, eds. Clinical Trial Methodology in Stroke. London, UK: Bailliere Tindall; 1989:75-90.
64. Warach S, Gaa J, Siewert B, Wielopolski P, Edelman RR. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neural. 1995;37:231-241.
65. Muller TB, Haraldseth O, Jones RA, Sebastiani G, Lindboe CF, Unsgard G, Oksendal AN. Perfusion and diffusion-weighted MR imaging for in vivo evaluation of treatment with U74389G in a rat stroke model. Stroke. 1995;26:1453-1458.
66. Minematsu K, Fisher M, Li L, Davis MA, Knapp AG, Cotter RE, McBurney RN, Sotak CH. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology. 1993;43:397-403.
67. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984;3:409-420.
68. Woods KL. Mega-trials and management of acute myocardial infarction. Lancet. 1995;346:611-614.
69. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P, Bogaert M, for the Multicentre Acute Stroke Trial Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet. 1995;345:57.
70. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.
71. Donnan GA, Davis S, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR. Trials of streptokinase in severe acute stroke: the Australian Streptokinase Study. Lancet. 1995;345:578-579.
72. Muir KW, Lees KR, Hamilton SJC, George CF, Hobbiger SF, Lunnon MW. A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke. In: Program of the Second International Conference on Neuroprotective Therapy: July 31-August 3, 1994; New York, NY. Abstract.
73. Otomo E, Araki G, Mon A, Kurihara M. Clinical evaluation of GABA in the treatment of cerebrovascular disorders: multi-center double blind study in comparison with pyrithioxine and placebo. Arzneimittelforschung. 1981;9:1511-1523.
74. Wahlgren NG, for the Class Study Group, The Chlormethiazole Acute Stroke Study (CLASS). Cerrebrovasc Dis. 1996:6:190. Abstract.
75. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss W-D. Effect of propentofylline on regional cerebral glucose metabolism in acute ischaemic stroke. J Cereb Blood Flow Metab. 1993;13:526-530.
76. Albers GW, Saenz RE, Moses JA, Choi DW. Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia. Stroke. 1991;22:1075-1077.
77. Albers GW, Atkinson R, Kelley R, Rosenbaum DM, for the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 1995;26:254-258. Abstract.
78. Fisher M, for the CNS 1102-003 Investigators. Cerestat (CNS 1102) a non-competitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study. Cerebrovasc Dis. 1994;4:245. Abstract.
79. Strand T, Wester PO, for the CVD Group. A double blind randomized pilot trial of magnesium therapy in acute cerebral infarction. In: Program of the 7th Nordic Meeting on Cerebrovascular Disease; Jyräskytlä Finland; August 14-17, p 37. Abstract.
80. Muir KW, Lees KR. A randomized double-blind placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke. 1995;26:1183-1188.
81. Grotta J, for the CGS19755 Study Group. Safety and tolerability of the glutamate antagonist CGS19755 in acute stroke patients. Stroke. 1994;25:255. Abstract.
82. Clark WM, Coull BM. Randomised trial of CGS19755, a glutamate antagonist in acute ischaemic stroke treatment. Neurology. 1994; 44(suppl 2):A270. Abstract.
83. Diener HC, Hacke W, Hennerici M, de Keyser J, Radberg J, Hantson L, for the LUB-INT-4 Study Group. The effects of lubeluzole in the acute treatment of ischemic stroke: results of a phase-2 trial. Stroke. 1995;26:185. Abstract.
84. Argentino C, Sacchetti ML, Toni D, Savoini G, D'Arcangelo E, Erminio F, Federico F, Milone FF, Gallai V, Gambi D, et al. GM1 ganglioside therapy in acute ischemic stroke. Stroke. 1989;20:1143-1149.
85. Hoffbrand BI, Bingley PJ, Oppenheimer SM, Sheldon CD. Trial of ganglioside GM1 in acute stroke. J Neural Neurosurg Psychiatry. 1988;51:1213-1214.